Table 3. Dose response relationship between duration of statin use and incidence of herpes zoster.
| Duration of statin use | Number of individuals (%) | Number of herpes zoster (%) | Odds ratio (95% CI) | Adjusteda odds ratio (95% CI) |
|---|---|---|---|---|
| Total | 25,726 (100) | 613 (100) | ||
| ~ 6 months | 14,896 (57.9) | 124 (0.83) | Reference | Reference |
| 6 ~ 12 months | 3,441 (13.4) | 81 (2.35) | 2.87 (2.17–3.81) | 2.57 (1.94–3.41) |
| 12 ~ 18 months | 1,746 (6.8) | 56 (3.21) | 3.95 (2.87–5.43) | 3.38 (2.45–4.66) |
| 18 ~ 24 months | 1,128 (4.4) | 66 (5.85) | 7.40 (5.46–10.04) | 6.29 (4.62–8.56) |
| 24 months ~ | 4,515 (17.6) | 286 (6.33) | 8.06 (6.51–9.97) | 6.57 (5.29–8.16) |
| p for trend | < 0.0001 | < 0.0001 |
Abbreviations: CI, confidential intervals
a Age and gender were adjusted for calculating odds ratio.